natgillin/translations-raw huggingface dataset:
Efficib is not recommended for use in children under 18 years of age because of a lack of information on safety and effectiveness in this group.
Uporaba zdravila Efficib pri otrocih, mlajših od 18 let, zaradi pomanjkanja informacij o varnosti in učinkovitosti v tej skupini ni priporočljiva.
The active substances in Efficib, sitagliptin and metformin hydrochloride, each have a different mode of action.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze (sladkorja) v krvi ali pri kateri telo ne more insulina učinkovito uporabljati.
It works by blocking the breakdown of 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Zdravilni učinkovini v zdravilu Efficib, sitagliptin in metforminijev klorid, imata obe 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. ‘ incretin’ hormones in the body.
Reproduction is authorised provided the source is acknowledged. različna načina delovanja.
These hormones are released after a meal and stimulate the pancreas to produce insulin.
Deluje tako, da zavira razgradnjo hormonov inkretinov v telesu.
By increasing the levels of incretin hormones in the blood, sitagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high.
Sitagliptin s povečanjem ravni hormonov inkretinov v krvi spodbudi trebušno slinavko k tvorjenju večjih količin insulina, kadar so ravni krvnega sladkorja previsoke.
Sitagliptin does not work when the blood glucose is low.
Sitagliptin ne učinkuje, ko je raven glukoze v krvi nizka.
Sitagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.
Sitagliptin zmanjša tudi količino sladkorja, ki ga tvorijo jetra, in sicer tako, da poviša raven insulina in zniža raven hormona glukagona.
Sitagliptin on its own has been approved by the European Union (EU) under the name Januvia since 2007.
Sitagliptin kot samostojno zdravilo je v Evropski uniji (EU) odobren pod imenom Januvia od leta 2007.
Januvia can be used with metformin, and with both metformin and a sulphonylurea, in type 2 diabetes patients.
Zdravilo Januvia se lahko uporablja z metforminom ter hkrati z metforminom in sulfonilsečnino pri bolnikih s sladkorno boleznijo tipa 2.
Three studies of Januvia, in patients with type 2 diabetes whose blood glucose levels were not adequately controlled on metformin alone, were used to support the use of Efficib in the same indications.
Tri študije zdravila Januvia z bolniki s sladkorno boleznijo tipa 2, katerih ravni glukoze v krvi niso zadostno nadzorovane samo z jemanjem metformina, so se uporabile v podporo uporabe zdravila Efficib pri istih indikacijah.
Two of the studies compared sitagliptin as an add-on to metformin with placebo (in 701 patients) and with glipizide (a sulphonylurea) (in 1,172 patients).
V dveh študijah so sitagliptin kot dodatek k metforminu primerjali s placebom (pri 701 bolniku) in z glipizidom (sulfonilsečnino) (pri 1172 bolnikih).
The third study compared sitagliptin with placebo, when used as an add-on to glimepiride (another sulphonylurea), with or without metformin, in 441 patients.
V tretji študiji so pri 441 bolnikih sitagliptin primerjali s placebom, ki so ga uporabili kot dodatek k glimepiridu (drugi vrsti sulfonilsečnine) z metforminom ali brez njega.
The results of one new study in patients who did not take antidiabetes medicines before were also presented, comparing the effect of sitagliptin plus metformin with that of metformin alone or sitagliptin alone.
Predstavljeni so bili tudi rezultati ene nove študije z bolniki, ki prej niso jemali zdravil proti sladkorni bolezni, v kateri so primerjali učinek kombinacije sitagliptina in metformina z učinkom metformina ali sitagliptina kot samostojnega zdravila.
All of the studies measured the change in the levels after 24 weeks of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
V vseh študijah so po 24 tednih merili spremembo koncentracije snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je glukoza v krvi nadzorovana.
Two ‘ bioequivalence’ studies were also carried out, showing that the active substances in the two strengths of Efficib were absorbed in the body in the same way as when they were taken as separate tablets.
Opravljeni sta bili tudi dve bioekvivalenčni študiji, ki prikazujeta, da sta bili zdravilni učinkovini v dveh jakostih zdravila Efficib absorbirani v telo enako kot takrat, ko sta bili vzeti v obliki ločenih tablet.
Sitagliptin taken in combination with metformin was more effective than metformin alone.
Sitagliptin je bil v kombinaciji z metforminom učinkovitejši od metformina, vzetega samostojno.
The addition of 100 mg sitagliptin to metformin reduced HbA1c levels by 0.67% (from around 8.0%) after 24 weeks, compared with a fall of 0.02% in the patients adding placebo.
Z dodajanjem 100 mg sitagliptina k metforminu so se ravni HbA1c po 24 tednih znižale za 0, 67% (z okoli 8, 0%) v primerjavi z znižanjem za 0, 02% pri bolnikih, katerim se je dodal placebo.
The effectiveness of adding sitagliptin to metformin was similar to that of glipizide in reducing the levels of HbA1c.
Učinkovitost dodajanja sitagliptina k metforminu je bila pri zniževanju ravni HbA1c podobna učinkovitosti glipizida.
In the study where sitagliptin was added to glimepiride and metformin, the levels of HbA1c were reduced by 0.59% after 24 weeks, compared with an increase of 0.30% in the patients adding placebo.
V študiji, pri kateri se je sitagliptin dodajal k glimepiridu in metforminu, so se ravni HbA1c po 24 tednih znižale za 0, 59% v primerjavi s povečanjem za 0, 30% pri bolnikih, pri katerih se je dodajal placebo.
In the new study, the combination of sitagliptin plus metformin was more effective than metformin or sitagliptin alone.
V novi študiji je bila kombinacija sitagliptina in metformina učinkovitejša od metformina ali sitagliptina kot samostojnega zdravila.
The most common side effect with Efficib (seen in between 1 and 10 patients in 100) is nausea (feeling sick).
Najpogostejši neželeni učinek zdravila Efficib (opažen pri 1 do 10 bolnikih izmed 100) je navzeja (občutek slabosti).
For the full list of all side effects reported with Efficib, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Efficib, glejte navodilo za uporabo.
Efficib should not be used in people who may be hypersensitive (allergic) to sitagliptin, metformin or any of the other ingredients.
Zdravila Efficib ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) sitagliptin, metformin ali katero koli drugo sestavino zdravila.
It should also not be used in patients who have diabetic ketoacidosis (high levels of ketones and acids in the blood), diabetic pre-coma, problems with their kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack.
Prav tako ga ne smejo uporabljati bolniki, ki imajo diabetično ketoacidozo (visoke koncentracije ketonov in kislin v krvi), diabetično komo, okvaro ledvic ali jeter, stanja, pri katerih obstaja možnost poslabšanja delovanja ledvic, ali bolezen, ki povzroči zmanjšanje pretoka kisika v tkiva, kot so srčna ali respiratorna odpoved ali nedavni srčni napad.
Why has Efficib been approved?
2/ 3 Zakaj je bilo zdravilo Efficib odobreno?
The Committee for Medicinal Products for Human Use (CHMP) decided that Efficib’ s benefits are greater than its risks for the treatment of patients with type 2 diabetes mellitus.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Efficib pri zdravljenju bolnikov s sladkorno boleznijo tipa 2 večje od z njim povezanih tveganj.
The Committee recommended that Efficib be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Efficib odobri dovoljenje za promet.
Other information about Efficib:
Druge informacije o zdravilu Efficib:
The European Commission granted a marketing authorisation valid throughout the EU for Efficib to Merck Sharp & Dohme Ltd on 16 July 2008.
Evropska komisija je dovoljenje za promet z zdravilom Efficib, veljavno po vsej Evropski uniji, odobrila družbi Merck Sharp & Dohme Ltd dne 16. julija 2008.
2/ 3 The full EPAR for Efficib can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Efficib je na voljo tukaj.
Efficib 50 mg/ 850 mg film-coated tablets
Efficib 50 mg/ 850 mg filmsko obložene tablete
Each tablet contains 50 mg of sitagliptin (as phosphate monohydrate) and 850 mg of metformin hydrochloride.
Vsaka tableta vsebuje 50 mg sitagliptina (v obliki sitagliptinijevega fosfata monohidrata) in 850 mg metforminijevega klorida.
Capsule-shaped, pink film-coated tablet with “ 515” debossed on one side.
Rožnate filmsko obložene tablete v obliki kapsule, z oznako "515" na eni strani.
For patients with type 2 diabetes mellitus:
Pri bolnikih s sladkorno boleznijo tipa 2:
Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Zdravilo Efficib je indicirano kot dodatek dieti in telesni vadbi za izboljšanje urejenosti glikemije pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka samega metformina, ki ga prenašajo, ali pri bolnikih, ki že prejemajo kombinacijo sitagliptina in metformina.
Efficib is also indicated in combination with a sulphonylurea (i. e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Zdravilo Efficib je indicirano tudi v kombinaciji s sulfonilsečnino (tj. trojno kombinirano zdravljenje) kot dodatek dieti in telesni vadbi pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka metformina, ki ga prenašajo, in sulfonilsečnine.
The dose of antihyperglycaemic therapy with Efficib should be individualised on the basis of the patient’ s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin.
Odmerek zdravila Efficib pri antidiabetičnem zdravljenju je treba prilagoditi na podlagi bolnikovega trenutnega režima zdravljenja, učinkovitosti in tolerabilnosti, pri tem pa se ne sme preseči največjega dovoljenega odmerka 100 mg sitagliptina.
For patients inadequately controlled on maximal tolerated dose of metformin monotherapy For patients not adequately controlled on metformin alone, the usual starting dose of Efficib should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken.
Pri bolnikih z neustreznim nadzorom z največjim odmerkom metformina, ki ga prenašajo, pri samostojnem zdravljenju Pri bolnikih, pri katerih nadzor z metforminom samim ni ustrezen, mora dejanski začetni odmerek zdravila Efficib zagotoviti odmerek 50 mg sitagliptina dvakrat na dan (skupni dnevni odmerek 100 mg) in odmerek metformina, ki ga že jemljejo.
For patients inadequately controlled on dual combination therapy with the maximal tolerated dose of metformin and a sulphonylurea The dose of Efficib should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.
Pri bolnikih z neustreznim nadzorom pri dvojni kombinaciji z največjim odmerkom metformina, ki ga prenašajo, in sulfonilsečnino Odmerek zdravila Efficib mora zagotoviti 50 mg sitagliptina dvakrat na dan (skupni dnevni odmerek 100 mg) in podoben odmerek metformina, kot ga že jemljejo.
When Efficib is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4).
Kadar se zdravilo Efficib uporablja v kombinaciji s sulfonilsečnino, bo morda potreben manjši odmerek sulfonilsečnine za zmanjševanje tveganja za hipoglikemijo (glejte poglavje 4. 4).
2 For the different doses on metformin, Efficib is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1000 mg metformin hydrochloride.
2 Za različne odmerke metformina je zdravilo Efficib na voljo v jakostih po 50 mg sitagliptina in 850 mg metforminijevega klorida ali 1. 000 mg metforminijevega klorida.
All patients should continue their diet with an adequate distribution of carbohydrate intake during the day.
Vsi bolniki morajo nadaljevati z dieto z ustrezno dnevno količino zaužitih ogljikovih hidratov.
Overweight patients should continue their energy-restricted diet.
Bolniki s preveliko telesno maso morajo nadaljevati z nizkokalorično dieto.
Efficib should be given twice daily with meals to reduce the gastrointestinal undesirable effects associated with metformin.
Zdravilo Efficib je treba jemati dvakrat na dan ob obroku, da se zmanjšajo neželeni učinki metformina na prebavila.
Patients with renal insufficiency Efficib should not be used in patients with moderate or severe renal impairment (creatinine clearance < 60 ml/ min) (see sections 4.3 and 4.4).
Bolniki z ledvično insuficienco Zdravila Efficib se ne sme uporabljati pri bolnikih z zmerno ali hudo ledvično okvaro (kreatininski očistek < 60 ml/ min) (glejte poglavji 4. 3 in 4. 4).
Patients with hepatic insufficiency Efficib should not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Bolniki z jetrno insuficienco Zdravila Efficib se pri bolnikih z okvaro jeter ne sme uporabljati (glejte poglavji 4. 3 in 5. 2).
Elderly As metformin and sitagliptin are excreted by the kidney, Efficib should be used with caution as age increases.
Starejši bolniki Metformin in sitagliptin se izločata skozi ledvice, zato je pri uporabi zdravila Efficib pri starejših potrebna previdnost.
Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in the elderly (see sections 4.3 and 4.4).
Spremljanje delovanja ledvic je nujno za preprečevanje laktacidoze, povezane z metforminom, zlasti pri starejših (glejte poglavji 4. 3 in 4. 4).
Limited safety data on sitagliptin is available in patients > 75 years of age and care should be exercised.
Za bolnike, stare > 75 let, je na voljo le malo podatkov o varnosti, zato je pri njih potrebna previdnost.
Paediatric population Efficib is not recommended for use in children below 18 years of age due to a lack of data on its safety and efficacy in this population.
Pediatrična populacija Zaradi pomanjkanja podatkov o varnosti in učinkovitosti v tej populaciji uporabe zdravila Efficib pri otrocih, mlajših od 18 let, ne priporočamo.
- hypersensitivity to the active substances or to any of the excipients (see sections 4.4 and 4.8);
- preobčutljivosti za zdravilni učinkovini ali katerokoli pomožno snov (glejte poglavji 4. 4 in 4. 8);
- diabetic ketoacidosis, diabetic pre-coma;
- diabetični ketoacidozi, stanju pred diabetično komo;
- moderate and severe renal impairment (creatinine clearance < 60 ml/ min) (see section 4.4);
- zmerni in hudi okvari ledvic (očistek kreatinina < 60 ml/ min) (glejte poglavje 4. 4);
- acute conditions with the potential to alter renal function such as:
- akutnih stanjih, pri katerih obstaja možnost poslabšanja delovanja ledvic, kot so:
dehydration, severe infection, shock, intravascular administration of iodinated contrast agents (see section 4.4);
dehidracija, huda okužba, šok, intravaskularna uporaba jodiranih kontrastnih sredstev (glejte poglavje 4. 4);
- acute or chronic disease which may cause tissue hypoxia such as:
- akutnih ali kroničnih boleznih, ki lahko povzročijo hipoksijo tkiv, kot so:
cardiac or respiratory failure, recent myocardial infarction, shock;
srčna ali respiratorna odpoved, nedavni miokardni infarkt, šok;
- hepatic impairment;
- okvari jeter,
- acute alcohol intoxication, alcoholism;
- akutni zastrupitvi z alkoholom, alkoholizmu;
- lactation.
- dojenju.
General Efficib should not be used in patients with type 1 diabetes and must not be used for the treatment of diabetic ketoacidosis.
Splošno Zdravila Efficib se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 in za zdravljenje diabetične ketoacidoze.
Lactic acidosis Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation.
Laktacidoza Laktacidoza je zelo redek, vendar nevaren presnovni zaplet (visoka stopnja smrtnosti, če se zdravljenje ne začne takoj), ki se lahko pojavi zaradi kopičenja metformina.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Poročila o primerih laktacidoze pri zdravljenju z metforminom se nanašajo predvsem na diabetike z napredovalo ledvično odpovedjo.
The incidence of lactic acidosis can and should be reduced by also assessing other associated
Incidenco laktacidoze je mogoče in tudi potrebno zmanjševati z oceno drugih povezanih dejavnikov
3 risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
3 tveganja, kot so slabo nadzorovana sladkorna bolezen, ketoza, dolgotrajno stradanje, čezmerno uživanje alkohola, jetrna insuficienca in katerakoli stanja, povezana s hipoksijo.
Diagnosis Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain and hypothermia followed by coma.
Diagnoza Za laktacidozo so značilne acidozna dispneja, abdominalna bolečina in hipotermija, ki jim sledi koma.
Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/ l, and an increased anion gap and lactate/ pyruvate ratio.
Diagnostični laboratorijski izvidi so znižan pH krvi, vrednosti laktata v plazmi nad 5 mmol/ l, zvečana anionska vrzel ter zvečana vrednost razmerja med laktatom in piruvatom.
If metabolic acidosis is suspected, treatment with the medicinal product should be discontinued and the patient hospitalised immediately (see section 4.9).
Ob sumu na metabolno acidozo je treba zdravljenje z zdravilom prekiniti in bolnika nemudoma hospitalizirati (glejte poglavje 4. 9).
Renal function Metformin and sitagliptin are known to be substantially excreted by the kidney.
Delovanje ledvic Metformin in sitagliptin se izločata večinoma skozi ledvice.
- at least two to four times a year in patients with serum creatinine levels at or above the upper
- vsaj dva - do štiri- krat letno pri bolnikih, ki imajo vrednosti kreatinina v serumu na zgornji
limit of normal and in elderly patients.
dovoljeni meji ali nad njo, in pri starejših bolnikih.
Hypoglycaemia Patients receiving Efficib in combination with a sulphonylurea may be at risk for hypoglycaemia.
Hipoglikemija Pri bolnikih, ki prejemajo zdravilo Efficib v kombinaciji s sulfonilsečnino, se lahko pojavi tveganje za hipoglikemijo.
Therefore, a reduction in the dose of the sulphonylurea may be necessary.
Zato je morda treba zmanjšati odmerek sulfonilsečnine.
The use of Efficib in combination with insulin has not been adequately studied.
Uporabe zdravila Efficib v kombinaciji z insulinom niso dovolj raziskali.
Hypersensitivity reactions Postmarketing reports of serious hypersensitivity reactions in patients treated with sitagliptin have been reported.
Preobčutljivostne reakcije V obdobju trženja so pri bolnikih, ki so prejemali sitagliptin, poročali o hudih preobčutljivostnih reakcijah.
These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome.
Med temi reakcijami so anafilaksa, angioedem in eksfoliativna stanja na koži, vključno s Stevens- Johnsonovim sindromom.
If a hypersensitivity reaction is suspected, discontinue Efficib, assess for other potential causes of the event, and institute alternative treatment for diabetes (see section 4.8).
Pri sumu na preobčutljivostne reakcije zdravljenje z zdravilom Efficib prekinite, ocenite druge morebitne vzroke za ta neželeni učinek in začnite zdraviti sladkorno bolezen z drugimi zdravili (glejte poglavje 4. 8).
Surgery As Efficib contains metformin hydrochloride, the treatment should be discontinued 48 hours before elective surgery with general, spinal or epidural anaesthesia.
Kirurški poseg Zdravilo Efficib vsebuje metforminijev klorid, zato je treba zdravljenje prekiniti 48 ur pred elektivno operacijo pod splošno, spinalno ali epiduralno anestezijo.
Efficib should not usually be resumed earlier than 48 hours afterwards and only after renal function has been re-evaluated and found to be normal.
Zdravljenje z zdravilom Efficib se sme nadaljevati šele 48 ur po posegu in šele, ko se ugotovi normalno delovanje ledvic.
Administration of iodinated contrast agent The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure which has been associated with lactic acidosis in patients receiving metformin.
Uporaba jodiranih kontrastnih sredstev Intravaskularna uporaba jodiranih kontrastnih sredstev pri radioloških pregledih lahko povzroči odpoved ledvic, povezano z laktacidozo, pri bolnikih, ki prejemajo metformin.
Therefore, Efficib should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Zdravljenje se sme nadaljevati šele 48 ur po posegu in šele, ko se ugotovi normalno delovanje ledvic (glejte poglavje 4. 5).
4 Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Efficib who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Spremembe kliničnega statusa pri bolnikih s predhodno nadzorovano sladkorno boleznijo tipa 2 Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Efficib, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels.
Pregled vključuje kontrolo elektrolitov in ketonov v serumu, glukoze v krvi in, če je indicirano, vrednost pH v krvi ter raven laktata, piruvata in metformina.
If acidosis of either form occurs, Efficib must be stopped immediately and other appropriate corrective measures initiated.
Če se pojavi acidoza v katerikoli obliki, je treba zdravljenje z zdravilom Efficib takoj prekiniti in primerno ukrepati.
4.5 Interaction with other medicinal products and other forms of interaction
4 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Co-administration of multiple doses of sitagliptin (50 mg twice daily) and metformin (1,000 mg twice daily) did not meaningfully alter the pharmacokinetics of either sitagliptin or metformin in patients with type 2 diabetes.
Sočasna uporaba večih odmerkov sitagliptina (50 mg dvakrat na dan) in metformina (1. 000 mg dvakrat na dan) ni pomembno spremenila farmakokinetike sitagliptina ali metformina pri bolnikih s sladkorno boleznijo tipa 2.
Pharmacokinetic drug interaction studies with Efficib have not been performed; however, such studies have been conducted with the individual active substances of Efficib, sitagliptin and metformin.
Študije farmakokinetičnih interakcij zdravila Efficib niso bile izvedene, vendar pa so take študije opravili s posameznima zdravilnima učinkovinama zdravila Efficib, sitagliptinom in metforminom.